All In Biotech

Drug Trial Radar · NCT07221253

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,100

Planned (sponsor's estimate)

Start

Dec 4, 2025

Primary completion

Jul 31, 2029

Study completion Jul 31, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

Conditions

  • Biliary Tract Cancer

Interventions

  • RilvegostomigDrug

    Rilvegostomig IV (intravenous) Q3W

  • DurvalumabDrug

    Durvalumab 1500mg IV (intravenous) Q3W for up to 8 cycles (21days). Then Q4W.

  • Gemcitabine/CisplatinDrug

    Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in the PDL1 ≥ 1% populationTime frame: approximately 4 years

Locations

183 sites in 19 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Tucson, Arizona · Recruiting

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Orange, California · Recruiting

  • Research Site

    Palo Alto, California · Recruiting

  • Research Site

    Aurora, Colorado · Recruiting

  • Research Site

    Hartford, Connecticut · Recruiting

  • Research Site

    New Haven, Connecticut · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Not yet recruiting

  • Research Site

    Gainesville, Florida · Recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Miami, Florida · Not yet recruiting

  • Research Site

    Marietta, Georgia · Recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Indianapolis, Indiana · Not yet recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Louisville, Kentucky · Withdrawn

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Ann Arbor, Michigan · Not yet recruiting

  • Research Site

    Detroit, Michigan · Not yet recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    Omaha, Nebraska · Not yet recruiting

  • Research Site

    Santa Fe, New Mexico · Recruiting

  • Research Site

    Mineola, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    Oklahoma City, Oklahoma · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Lancaster, Pennsylvania · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Providence, Rhode Island · Recruiting

  • Research Site

    Pierre, South Dakota · Recruiting

  • Research Site

    Sioux Falls, South Dakota · Recruiting

  • Research Site

    Nashville, Tennessee · Not yet recruiting

Showing 40 of 183 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.